GB0511750D0 - Method of increasing bioavailability of alendronate or other bis-phosphonate by predose administration of vitamin d derivative - Google Patents

Method of increasing bioavailability of alendronate or other bis-phosphonate by predose administration of vitamin d derivative

Info

Publication number
GB0511750D0
GB0511750D0 GBGB0511750.2A GB0511750A GB0511750D0 GB 0511750 D0 GB0511750 D0 GB 0511750D0 GB 0511750 A GB0511750 A GB 0511750A GB 0511750 D0 GB0511750 D0 GB 0511750D0
Authority
GB
United Kingdom
Prior art keywords
alendronate
phosphonate
vitamin
bis
derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
GBGB0511750.2A
Other versions
GB2411116B (en
GB2411116A (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Original Assignee
Teva Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd filed Critical Teva Pharmaceutical Industries Ltd
Publication of GB0511750D0 publication Critical patent/GB0511750D0/en
Publication of GB2411116A publication Critical patent/GB2411116A/en
Application granted granted Critical
Publication of GB2411116B publication Critical patent/GB2411116B/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
GB0511750A 2002-12-16 2003-12-16 Increasing the bioavailability of alendronate by predose administration of alphacalcidol Expired - Fee Related GB2411116B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US43368502P 2002-12-16 2002-12-16
US46020603P 2003-04-02 2003-04-02
PCT/US2003/040174 WO2004058235A2 (en) 2002-12-16 2003-12-16 Method of increasing bioavailability of alendronate or other bis-phosphonate by predose administration of vitamin d derivative

Publications (3)

Publication Number Publication Date
GB0511750D0 true GB0511750D0 (en) 2005-07-20
GB2411116A GB2411116A (en) 2005-08-24
GB2411116B GB2411116B (en) 2009-04-29

Family

ID=32685268

Family Applications (1)

Application Number Title Priority Date Filing Date
GB0511750A Expired - Fee Related GB2411116B (en) 2002-12-16 2003-12-16 Increasing the bioavailability of alendronate by predose administration of alphacalcidol

Country Status (7)

Country Link
JP (3) JP2006514695A (en)
AU (1) AU2003300984A1 (en)
DE (1) DE10393906T5 (en)
GB (1) GB2411116B (en)
HK (1) HK1078802A1 (en)
IL (1) IL169127A0 (en)
WO (1) WO2004058235A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8426391B2 (en) 2006-02-03 2013-04-23 Proventiv Therapeutics, Llc Treating vitamin D insufficiency and deficiency with 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3
WO2007094779A1 (en) * 2006-02-14 2007-08-23 Teva Pharmaceutical Industries Ltd. Pharmaceutical formulations of aliphatic amine polymers and methods for their manufacture
SI2679228T1 (en) 2006-06-21 2018-06-29 Opko Ireland Global Holdings, Ltd. Therapy using vitamin D repletion agent and vitamin D hormone replacement agent
CA2671727C (en) * 2006-12-20 2016-02-16 Genpharm Ulc A composition containing a bisphosphonic acid in combination with vitamin d
WO2008074145A1 (en) * 2006-12-20 2008-06-26 Genpharm Ulc Pharmaceutical composition comprising a hot-melt granulated lubricant
ES2403107T3 (en) 2007-04-25 2013-05-14 Cytochroma Inc. Vitamin D insufficiency and deficiency treatment method
DK3342405T3 (en) 2007-04-25 2019-11-11 Opko Ireland Global Holdings Ltd CONTROLLED RELEASE OF 25-HYDROXYVITAMINE D
EP2148685A4 (en) 2007-04-25 2010-07-28 Cytochroma Inc Methods and compounds for vitamin d therapy
WO2008134523A1 (en) 2007-04-25 2008-11-06 Proventiv Therapeutics, Llc Method of safely and effectively treating and preventing secondary hyperparathyroidism in chronic kidney disease
KR101852042B1 (en) 2008-04-02 2018-04-25 사이토크로마 인코포레이티드 Methods, compositions, uses, and kits useful for vitamin d deficiency and related disorders
EP3636280A1 (en) 2010-03-29 2020-04-15 Opko Ireland Global Holdings, Ltd. Methods and compositions for reducing parathyroid levels
KR101847947B1 (en) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 Stabilized modified release vitamin d formulation
SG10201911274TA (en) 2014-08-07 2020-02-27 Opko Ireland Global Holdings Ltd Adjunctive therapy with 25-hydroxyvitamin d
SG10201913863TA (en) 2016-03-28 2020-03-30 Opko Ireland Global Holdings Limited Methods of vitamin d treatment
CN109364034B (en) * 2018-11-26 2021-05-04 正大制药（青岛）有限公司 Calcitriol preparation and preparation method thereof
CN116211818B (en) * 2023-03-10 2024-04-09 菲洋生物科技(吉林)有限公司 Tablet containing alendronate sodium and preparation method thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100317935B1 (en) * 1999-10-20 2001-12-22 유승필 Pharmaceutical compositions and preparations for treatment of metabolic bone disease
CA2454200A1 (en) * 2001-07-17 2003-01-30 Teva Pharmaceutical Industries Ltd. Dosage forms for immediate gastric release of a calcium transport stimulator coupled with delayed gastric release of a bis-phosphonate

Also Published As

Publication number Publication date
AU2003300984A8 (en) 2004-07-22
HK1078802A1 (en) 2006-03-24
JP2014205711A (en) 2014-10-30
IL169127A0 (en) 2009-02-11
DE10393906T5 (en) 2006-01-12
GB2411116B (en) 2009-04-29
WO2004058235A2 (en) 2004-07-15
WO2004058235A3 (en) 2005-02-24
AU2003300984A1 (en) 2004-07-22
JP2006514695A (en) 2006-05-11
GB2411116A (en) 2005-08-24
JP2011241221A (en) 2011-12-01

Similar Documents

Publication Publication Date Title
IL169127A0 (en) Method of increasing bioavailability of alendronate or other bis-phosphonate by predose administration of vitamin d derivative
AU2003280373A1 (en) Method of administering bisphosphonates
EP1477119A4 (en) Drug administration method
AU2003272590A1 (en) Method for ophtalmic administration of medicament
ZA200508178B (en) A method for the prevention of malaria infection of humans by hepatocyte growth factor antagonists
EP1507559A4 (en) Delivery of microparticle-conjugated drugs for inhibition of stenosis
PL375558A1 (en) A method of extending the dose range of vitamin d compounds
AU2002244881A1 (en) Controlled release drug delivery system of pravastatin
PT1753393T (en) Method for the innoformulation of a biocompatible galenic base
AU2003221699A1 (en) Pharmaceutical preparation for taste masking
EP1683525A4 (en) Sustained-release phenylalanine derivative preparation for oral administration
IL169352A0 (en) Improved method for the production of vitamin b12
AU2003270486A1 (en) Tie-back connection for subsea well
IL165691A0 (en) Epimerization of analogs of vitamin D
EP1498420A4 (en) Phospholipid derivative
GB0220740D0 (en) Administration of a system
EP1646640A4 (en) Method for the preparation of highly pure 1-androstene derivatives
AP1925A (en) Method for the prevention of malaria
AU2003269050A1 (en) Method for decreasing bioavailability variability of an orally administered medicine
AU2003302116A1 (en) Method of preparation of derivatives of substituted 2-aryl aikanoic acids
AU2003266714A8 (en) Phospholipid derivative
AU2003244092A1 (en) 1ss-METHYLCARBAPENEM DERIVATIVE FOR ORAL ADMINISTRATION
GB0328040D0 (en) Pharmaceutical uses of bisphosphonates
AU2003226696A1 (en) Improved method for the production of vitamin b12
AU2003200836A1 (en) Method for the preparation of matairesinol

Legal Events

Date Code Title Description
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1078802

Country of ref document: HK

R108 Alteration of time limits (patents rules 1995)

Free format text: EXTENSION ALLOWED

Effective date: 20090318

Free format text: EXTENSION APPLICATION

Effective date: 20090311

REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1078802

Country of ref document: HK

PCNP Patent ceased through non-payment of renewal fee

Effective date: 20151216